th_G5e8MYJMM4dp5EJKHyp3Rcdu557nNJyRE5UQjMqx4WAzGXkTL of Aeternity

SpendTx
block_hash	mh_2DSJkrtcLTYahKgjmP2DmCVPW5b8amdiCTHiss2XDmBE9V9c9L
block_height	250804 830850 blocks confirmed
encoded_tx	tx_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
hash	th_G5e8MYJMM4dp5EJKHyp3Rcdu557nNJyRE5UQjMqx4WAzGXkTL
signatures	sg_YaxtM5YWFfVruZWpiQvgs96W3ZNxwYq3dt85TUvLrNkaV7rMF8QnLDN6RbwRtN679xqtDauWBhUVdBAAXNc9nnwn2jK8V
Tx
	amount	0.1 AE(100000000000000000 ættos )
	fee	0.000055380000000000 AE(55380000000000 ættos )
	nonce	4
	payload	ba_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 (Decoded: {"WeTrue":"0.5.3","content_type":"main","wet_content":"\nPreliminary data from a clinical trial led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) showed that Gilead Sciences’ remdesivir led to faster recovery in Covid-19 patients.\n\nTheACTT trial, which involved 1063 hospitalised patients with advanced Covid-19 and lung involvement, compared the experimental antiviral drug to placebo.\n\nAn interim analysis by the independent data and safety monitoring board (DSMB) found that remdesivir performed better on the primary endpoint of ‘time to recovery’ when compared to placebo.\n\nResults showed a 31% faster time to recovery in patients treated with Gilead’s drug versus placebo. The median time to recovery was 11 days versus 15 days, respectively.\n\nNIH also noted a survival benefit, where remdesivir group had 8% mortality rate compared to 11.6% with placebo.\n\nCommenting on the trial data, NIH said: “More detailed information about the trial results, including more compreh\n\nFurthermore, Gilead has reported top-line data from the open-label,Phase III SIMPLE trialof remdesivir.\n\nThe trial assessed five-day and ten-day dosing durations of the drug in hospitalised patients suffering from severe Covid-19 manifestations .\n\nAccording to the top-line results, patients on a ten-day treatment course experienced an improvement in clinical status that was similar to those on a five-day dosing course.\n\nThe investigators did not report any new safety signals in either treatment group. The drug was generally well-tolerated in both the treatment arms.\n\nThe most common adverse events in more than 10% of participants in either group were nausea and acute respiratory failure.\n\nResults from the second SIMPLE trial in patients with moderate Covid-19 manifestations are expected to be available by the end of next month.","img_list":""})
	recipient_id	ak_dMyzpooJ4oGnBVX35SCvHspJrq55HAAupCwPQTDZmRDT5SSSW
	sender_id	ak_2u9k4ZqbgRFLEYSU9Zjk5JLfnbvURt9MUsqNbmfcLBqjn1DnN5
	type	SpendTx
version	1

th_G5e8MYJMM4dp5EJKHyp3Rcdu557nNJyRE5UQjMqx4WAzGXkTL details

SpendTx